Skip to main content
Top
Published in: Malaria Journal 1/2012

Open Access 01-12-2012 | Research

Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii

Authors: Rubul Mout, Zhi-Dong Xu, Angela K H Wolf, Vincent Jo Davisson, Gotam K Jarori

Published in: Malaria Journal | Issue 1/2012

Login to get access

Abstract

Background

Geldanamycin (GA), a benzoquinone ansamycin antibiotic has been shown in vitro to possess anti-plasmodial activity. Pharmacological activity of this drug is attributed to its ability to inhibit PfHSP90. The parasite growth arrest has been shown to be due to drug-induced blockage of the transition from ring to trophozoite stage. To further evaluate the consequences of this pharmacodyamic feature, the anti-malarial activity of GA analogs with enhanced drug properties in a Plasmodium-infected animal model have been evaluated for their capacity to induce clearance of the parasite. In the process, a hypothesis was subsequently tested regarding the susceptibility of the cured animals to malaria reflected in an attenuated parasite load that may be evoked by a protective immune response in the host.

Methods

Six weeks old Swiss mice were infected with a lethal Plasmodium yoelii (17XL) strain. On appearance of clinical symptoms of malaria, these animals were treated with two different GA derivatives and the parasite load was monitored over 15-16 days. Drug-treated animals cured of the parasite were then re-challenged with a lethal dose of P. yoelii 17XL. Serum samples from GA cured mice that were re-challenged with P. yoelii 17XL were examined for the presence of antibodies against the parasite proteins using western blot analysis.

Results

Treatment of P. yoelii 17XL infected mice with GA derivatives showed slow recovery from clinical symptoms of the disease. Blood smears from drug treated mice indicated a dominance of ring stage parasites when compared to controls. Although, P. yoelii preferentially invades normocytes (mature rbcs), in drug-treated animals there was an increased invasion of reticulocytes. Cured animals exhibited robust protection against subsequent infection and serum samples from these animals showed antibodies against a vast majority of parasite proteins.

Conclusions

Treatment with GA derivatives blocked the transition from ring to trophozoite stage presumably by the inhibition of HSP90 associated functions. Persistence of parasite in ring stage leads to robust humoral immune response as well as a shift in invasion specificity from normocytes to reticulocyte. It is likely that the treatment with the water-soluble GA derivative creates an attenuated state (less virulent with altered invasion specificity) that persists in the host system, allowing it to mount a robust immune response.
Appendix
Available only for authorised users
Literature
2.
go back to reference Dhingra N, Jha P, Sharma VP, Cohen AA, Jotkar RM, Rodriguez PS, Bassani DG, Suraweera W, Laxminarayan R, Peto R: Adult and child malaria mortality in India: a nationally representative mortality survey. Lancet. 2010, 376: 1768-1774. 10.1016/S0140-6736(10)60831-8.PubMedCentralCrossRefPubMed Dhingra N, Jha P, Sharma VP, Cohen AA, Jotkar RM, Rodriguez PS, Bassani DG, Suraweera W, Laxminarayan R, Peto R: Adult and child malaria mortality in India: a nationally representative mortality survey. Lancet. 2010, 376: 1768-1774. 10.1016/S0140-6736(10)60831-8.PubMedCentralCrossRefPubMed
3.
go back to reference Beeson JG, Osier FH, Engwerda CR: Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol. 2008, 24: 578-584. 10.1016/j.pt.2008.08.008.CrossRefPubMed Beeson JG, Osier FH, Engwerda CR: Recent insights into humoral and cellular immune responses against malaria. Trends Parasitol. 2008, 24: 578-584. 10.1016/j.pt.2008.08.008.CrossRefPubMed
5.
go back to reference Epstein JE, Giersing B, Mullen G, Moorthy V, Richie TL: Malaria vaccines: are we getting closer?. Curr Opin Mol Ther. 2007, 9: 12-24.PubMed Epstein JE, Giersing B, Mullen G, Moorthy V, Richie TL: Malaria vaccines: are we getting closer?. Curr Opin Mol Ther. 2007, 9: 12-24.PubMed
6.
go back to reference Ridley RG: Medical need, scientific opportunity and the drive for antimalarial drugs. Nature. 2002, 415: 686-693. 10.1038/415686a.CrossRefPubMed Ridley RG: Medical need, scientific opportunity and the drive for antimalarial drugs. Nature. 2002, 415: 686-693. 10.1038/415686a.CrossRefPubMed
7.
go back to reference Ridley RG: Antimalarial drug resistance: ramifications, explanations and challenges. Microbes Infect. 2002, 4: 155-156. 10.1016/S1286-4579(01)01536-2.CrossRefPubMed Ridley RG: Antimalarial drug resistance: ramifications, explanations and challenges. Microbes Infect. 2002, 4: 155-156. 10.1016/S1286-4579(01)01536-2.CrossRefPubMed
8.
go back to reference Hyde JE: Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 2002, 4: 165-174. 10.1016/S1286-4579(01)01524-6.CrossRefPubMed Hyde JE: Mechanisms of resistance of Plasmodium falciparum to antimalarial drugs. Microbes Infect. 2002, 4: 165-174. 10.1016/S1286-4579(01)01524-6.CrossRefPubMed
11.
go back to reference Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002, 419: 498-511. 10.1038/nature01097.CrossRefPubMed Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, Carlton JM, Pain A, Nelson KE, Bowman S, Paulsen IT, James K, Eisen JA, Rutherford K, Salzberg SL, Craig A, Kyes S, Chan MS, Nene V, Shallom SJ, Suh B, Peterson J, Angiuoli S, Pertea M, Allen J, Selengut J, Haft D, Mather MW, Vaidya AB, Martin DM, Fairlamb AH, Fraunholz MJ, Roos DS, Ralph SA, McFadden GI, Cummings LM, Subramanian GM, Mungall C, Venter JC, Carucci DJ, Hoffman SL, Newbold C, Davis RW, Fraser CM, Barrell B: Genome sequence of the human malaria parasite Plasmodium falciparum. Nature. 2002, 419: 498-511. 10.1038/nature01097.CrossRefPubMed
12.
go back to reference Brady RL, Cameron A: Structure-based approaches to the development of novel anti-malarials. Curr Drug Targets. 2004, 5: 137-149. 10.2174/1389450043490587.CrossRefPubMed Brady RL, Cameron A: Structure-based approaches to the development of novel anti-malarials. Curr Drug Targets. 2004, 5: 137-149. 10.2174/1389450043490587.CrossRefPubMed
13.
go back to reference Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT: Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010, 329: 1175-1180. 10.1126/science.1193225.PubMedCentralCrossRefPubMed Rottmann M, McNamara C, Yeung BK, Lee MC, Zou B, Russell B, Seitz P, Plouffe DM, Dharia NV, Tan J, Cohen SB, Spencer KR, González-Páez GE, Lakshminarayana SB, Goh A, Suwanarusk R, Jegla T, Schmitt EK, Beck HP, Brun R, Nosten F, Renia L, Dartois V, Keller TH, Fidock DA, Winzeler EA, Diagana TT: Spiroindolones, a potent compound class for the treatment of malaria. Science. 2010, 329: 1175-1180. 10.1126/science.1193225.PubMedCentralCrossRefPubMed
14.
go back to reference DeBoer C, Meulman PA, Wnuk RJ, Peterson DH: Geldanamycin, a new antibiotic. J Antibiot (Tokyo). 1970, 23: 442-447. 10.7164/antibiotics.23.442.CrossRef DeBoer C, Meulman PA, Wnuk RJ, Peterson DH: Geldanamycin, a new antibiotic. J Antibiot (Tokyo). 1970, 23: 442-447. 10.7164/antibiotics.23.442.CrossRef
15.
go back to reference Shonhai A: Plasmodial heat shock proteins: targets for chemotherapy. FEMS Immunol Med Microbiol. 2010, 58: 61-74. 10.1111/j.1574-695X.2009.00639.x.CrossRefPubMed Shonhai A: Plasmodial heat shock proteins: targets for chemotherapy. FEMS Immunol Med Microbiol. 2010, 58: 61-74. 10.1111/j.1574-695X.2009.00639.x.CrossRefPubMed
16.
go back to reference Li LH, Clark TD, Cowie CH, Rinehart KL: Effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of Rauscher leukemia virus. Cancer Treat Rep. 1977, 61: 815-824.PubMed Li LH, Clark TD, Cowie CH, Rinehart KL: Effects of geldanamycin and its derivatives on RNA-directed DNA polymerase and infectivity of Rauscher leukemia virus. Cancer Treat Rep. 1977, 61: 815-824.PubMed
17.
go back to reference Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM: Inhibition of heat shock protein HSP90-pp 60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994, 91: 8324-8328. 10.1073/pnas.91.18.8324.PubMedCentralCrossRefPubMed Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM: Inhibition of heat shock protein HSP90-pp 60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci USA. 1994, 91: 8324-8328. 10.1073/pnas.91.18.8324.PubMedCentralCrossRefPubMed
18.
go back to reference Acharya P, Kumar R, Tatu U: Chaperoning a cellular upheaval in malaria: heat shock proteins in Plasmodium falciparum. Mol Biochem Parasitol. 2007, 153: 85-94. 10.1016/j.molbiopara.2007.01.009.CrossRefPubMed Acharya P, Kumar R, Tatu U: Chaperoning a cellular upheaval in malaria: heat shock proteins in Plasmodium falciparum. Mol Biochem Parasitol. 2007, 153: 85-94. 10.1016/j.molbiopara.2007.01.009.CrossRefPubMed
19.
go back to reference Banumathy G, Singh V, Pavithra SR, Tatu U: Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem. 2003, 278: 18336-18345. 10.1074/jbc.M211309200.CrossRefPubMed Banumathy G, Singh V, Pavithra SR, Tatu U: Heat shock protein 90 function is essential for Plasmodium falciparum growth in human erythrocytes. J Biol Chem. 2003, 278: 18336-18345. 10.1074/jbc.M211309200.CrossRefPubMed
20.
go back to reference Kumar R, Musiyenko A, Barik S: The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Malar J. 2003, 2: 30-10.1186/1475-2875-2-30.PubMedCentralCrossRefPubMed Kumar R, Musiyenko A, Barik S: The heat shock protein 90 of Plasmodium falciparum and antimalarial activity of its inhibitor, geldanamycin. Malar J. 2003, 2: 30-10.1186/1475-2875-2-30.PubMedCentralCrossRefPubMed
21.
go back to reference Kumar R, Musiyenko A, Barik S: Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. Mol Biochem Parasitol. 2005, 141: 29-37. 10.1016/j.molbiopara.2005.01.012.CrossRefPubMed Kumar R, Musiyenko A, Barik S: Plasmodium falciparum calcineurin and its association with heat shock protein 90: mechanisms for the antimalarial activity of cyclosporin A and synergism with geldanamycin. Mol Biochem Parasitol. 2005, 141: 29-37. 10.1016/j.molbiopara.2005.01.012.CrossRefPubMed
22.
go back to reference Supko JG, Hickman RL, Grever MR, Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995, 36: 305-315. 10.1007/BF00689048.CrossRefPubMed Supko JG, Hickman RL, Grever MR, Malspeis L: Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995, 36: 305-315. 10.1007/BF00689048.CrossRefPubMed
23.
go back to reference Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005, 23: 1885-1893. 10.1200/JCO.2005.12.085.CrossRefPubMed Grem JL, Morrison G, Guo XD, Agnew E, Takimoto CH, Thomas R, Szabo E, Grochow L, Grollman F, Hamilton JM, Neckers L, Wilson RH: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J Clin Oncol. 2005, 23: 1885-1893. 10.1200/JCO.2005.12.085.CrossRefPubMed
24.
go back to reference Agnew EB, Wilson RH, Grem JL, Neckers L, Bi D, Takimoto CH: Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001, 755: 237-243. 10.1016/S0378-4347(01)00113-X.CrossRefPubMed Agnew EB, Wilson RH, Grem JL, Neckers L, Bi D, Takimoto CH: Measurement of the novel antitumor agent 17-(allylamino)-17-demethoxygeldanamycin in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl. 2001, 755: 237-243. 10.1016/S0378-4347(01)00113-X.CrossRefPubMed
25.
go back to reference Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC: Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem. 2004, 12: 5317-5329. 10.1016/j.bmc.2004.07.053.CrossRefPubMed Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, Myles DC: Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem. 2004, 12: 5317-5329. 10.1016/j.bmc.2004.07.053.CrossRefPubMed
26.
go back to reference Pal-Bhowmick I, Vora HK, Jarori GK: Sub-cellular localization and post-translational modifications of the Plasmodium yoelii enolase suggest moonlighting functions. Malar J. 2007, 6: 45-10.1186/1475-2875-6-45.PubMedCentralCrossRefPubMed Pal-Bhowmick I, Vora HK, Jarori GK: Sub-cellular localization and post-translational modifications of the Plasmodium yoelii enolase suggest moonlighting functions. Malar J. 2007, 6: 45-10.1186/1475-2875-6-45.PubMedCentralCrossRefPubMed
27.
go back to reference Pal-Bhowmick I, Sadagopan K, Vora HK, Sehgal A, Sharma S, Jarori GK: Cloning, over-expression, purification and characterization of Plasmodium falciparum enolase. Eur J Biochem. 2004, 271: 4845-4854. 10.1111/j.1432-1033.2004.04450.x.CrossRefPubMed Pal-Bhowmick I, Sadagopan K, Vora HK, Sehgal A, Sharma S, Jarori GK: Cloning, over-expression, purification and characterization of Plasmodium falciparum enolase. Eur J Biochem. 2004, 271: 4845-4854. 10.1111/j.1432-1033.2004.04450.x.CrossRefPubMed
28.
go back to reference Jayawardena AN, Mogil R, Murphy DB, Burger D, Gershon RK: Enhanced expression of H-2 K and H-2D antigens on reticulocytes infected with Plasmodium yoelii. Nature. 1983, 302: 623-626. 10.1038/302623a0.CrossRefPubMed Jayawardena AN, Mogil R, Murphy DB, Burger D, Gershon RK: Enhanced expression of H-2 K and H-2D antigens on reticulocytes infected with Plasmodium yoelii. Nature. 1983, 302: 623-626. 10.1038/302623a0.CrossRefPubMed
29.
go back to reference Swardson-Olver CJ, Dawson TC, Burnett RC, Peiper SC, Maeda N, Avery AC: Plasmodium yoelii uses the murine Duffy antigen receptor for chemokines as a receptor for normocyte invasion and an alternative receptor for reticulocyte invasion. Blood. 2002, 99: 2677-2684. 10.1182/blood.V99.8.2677.CrossRefPubMed Swardson-Olver CJ, Dawson TC, Burnett RC, Peiper SC, Maeda N, Avery AC: Plasmodium yoelii uses the murine Duffy antigen receptor for chemokines as a receptor for normocyte invasion and an alternative receptor for reticulocyte invasion. Blood. 2002, 99: 2677-2684. 10.1182/blood.V99.8.2677.CrossRefPubMed
30.
go back to reference Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem. 2002, 277: 39858-39866. 10.1074/jbc.M206322200.CrossRefPubMed Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N: Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem. 2002, 277: 39858-39866. 10.1074/jbc.M206322200.CrossRefPubMed
31.
go back to reference Basso AD, Solit DB, Munster PN, Rosen N: Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002, 21: 1159-1166. 10.1038/sj.onc.1205184.PubMedCentralCrossRefPubMed Basso AD, Solit DB, Munster PN, Rosen N: Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene. 2002, 21: 1159-1166. 10.1038/sj.onc.1205184.PubMedCentralCrossRefPubMed
32.
go back to reference Pearl LH, Prodromou C: Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem. 2001, 59: 157-186.CrossRefPubMed Pearl LH, Prodromou C: Structure, function, and mechanism of the Hsp90 molecular chaperone. Adv Protein Chem. 2001, 59: 157-186.CrossRefPubMed
33.
go back to reference Richter K, Buchner J: Hsp90: chaperoning signal transduction. J Cell Physiol. 2001, 188: 281-290. 10.1002/jcp.1131.CrossRefPubMed Richter K, Buchner J: Hsp90: chaperoning signal transduction. J Cell Physiol. 2001, 188: 281-290. 10.1002/jcp.1131.CrossRefPubMed
34.
go back to reference Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005, 23: 4152-4161. 10.1200/JCO.2005.00.612.CrossRefPubMed Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I: Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol. 2005, 23: 4152-4161. 10.1200/JCO.2005.00.612.CrossRefPubMed
35.
go back to reference Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM: Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003, 21: 3761-3769. 10.1200/JCO.2003.01.238.CrossRefPubMed Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM: Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol. 2003, 21: 3761-3769. 10.1200/JCO.2003.01.238.CrossRefPubMed
36.
go back to reference Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C: A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res. 2006, 12: 6087-6093. 10.1158/1078-0432.CCR-06-1015.CrossRefPubMed Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C: A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res. 2006, 12: 6087-6093. 10.1158/1078-0432.CCR-06-1015.CrossRefPubMed
37.
go back to reference Wiesgigl M, Clos J: The heat shock protein 90 of Leishmania donovani. Med Microbiol Immunol. 2001, 190: 27-31.CrossRefPubMed Wiesgigl M, Clos J: The heat shock protein 90 of Leishmania donovani. Med Microbiol Immunol. 2001, 190: 27-31.CrossRefPubMed
38.
39.
go back to reference Devaney E, O'Neill K, Harnett W, Whitesell L, Kinnaird JH: Hsp90 is essential in the filarial nematode Brugia pahangi. Int J Parasitol. 2005, 35: 627-636. 10.1016/j.ijpara.2005.01.007.CrossRefPubMed Devaney E, O'Neill K, Harnett W, Whitesell L, Kinnaird JH: Hsp90 is essential in the filarial nematode Brugia pahangi. Int J Parasitol. 2005, 35: 627-636. 10.1016/j.ijpara.2005.01.007.CrossRefPubMed
40.
go back to reference Wenkert D, Ramirez B, Shen Y, Kron MA: In vitr activity of geldanamycin derivatives against Schistosoma japonicum and Brugia malayi. J Parasitol Res. 2010, 2010: 716498-PubMedCentralCrossRefPubMed Wenkert D, Ramirez B, Shen Y, Kron MA: In vitr activity of geldanamycin derivatives against Schistosoma japonicum and Brugia malayi. J Parasitol Res. 2010, 2010: 716498-PubMedCentralCrossRefPubMed
41.
go back to reference David CL, Smith HE, Raynes DA, Pulcini EJ, Whitesell L: Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans. Cell Stress Chaperones. 2003, 8: 93-104. 10.1379/1466-1268(2003)8<93:EOAUDH>2.0.CO;2.PubMedCentralCrossRefPubMed David CL, Smith HE, Raynes DA, Pulcini EJ, Whitesell L: Expression of a unique drug-resistant Hsp90 ortholog by the nematode Caenorhabditis elegans. Cell Stress Chaperones. 2003, 8: 93-104. 10.1379/1466-1268(2003)8<93:EOAUDH>2.0.CO;2.PubMedCentralCrossRefPubMed
42.
43.
go back to reference Clyde DF, Most H, McCarthy VC, Vanderberg JP: Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973, 266: 169-177. 10.1097/00000441-197309000-00002.CrossRefPubMed Clyde DF, Most H, McCarthy VC, Vanderberg JP: Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci. 1973, 266: 169-177. 10.1097/00000441-197309000-00002.CrossRefPubMed
44.
go back to reference Vaughan AM, Wang R, Kappe SH: Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin. 2010, 6: 107-113. 10.4161/hv.6.1.9654.PubMedCentralCrossRefPubMed Vaughan AM, Wang R, Kappe SH: Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin. 2010, 6: 107-113. 10.4161/hv.6.1.9654.PubMedCentralCrossRefPubMed
46.
go back to reference Targett GA, Greenwood BM: Malaria vaccines and their potential role in the elimination of malaria. Malar J. 2008, 7 (Suppl 1): S10-10.1186/1475-2875-7-S1-S10.PubMedCentralCrossRefPubMed Targett GA, Greenwood BM: Malaria vaccines and their potential role in the elimination of malaria. Malar J. 2008, 7 (Suppl 1): S10-10.1186/1475-2875-7-S1-S10.PubMedCentralCrossRefPubMed
47.
go back to reference Greenwood B, Targett G: The mysteries of immunity to malaria. Lancet. 2011, 377: 1729-1730. 10.1016/S0140-6736(11)60515-1.CrossRefPubMed Greenwood B, Targett G: The mysteries of immunity to malaria. Lancet. 2011, 377: 1729-1730. 10.1016/S0140-6736(11)60515-1.CrossRefPubMed
48.
go back to reference Sauerwein RW, Bijker EM, Richie TL: Empowering malaria vaccination by drug administration. Curr Opin Immunol. 2010, 22: 367-373. 10.1016/j.coi.2010.04.001.CrossRefPubMed Sauerwein RW, Bijker EM, Richie TL: Empowering malaria vaccination by drug administration. Curr Opin Immunol. 2010, 22: 367-373. 10.1016/j.coi.2010.04.001.CrossRefPubMed
49.
go back to reference Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T: Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009, 361: 468-477. 10.1056/NEJMoa0805832.CrossRefPubMed Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T: Protection against a malaria challenge by sporozoite inoculation. N Engl J Med. 2009, 361: 468-477. 10.1056/NEJMoa0805832.CrossRefPubMed
50.
go back to reference Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW: Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011, 377: 1770-1776. 10.1016/S0140-6736(11)60360-7.CrossRefPubMed Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW: Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet. 2011, 377: 1770-1776. 10.1016/S0140-6736(11)60360-7.CrossRefPubMed
51.
go back to reference Culleton R, Kaneko O: Erythrocyte binding ligands in malaria parasites: intracellular trafficking and parasite virulence. Acta Trop. 2010, 114: 131-137. 10.1016/j.actatropica.2009.10.025.CrossRefPubMed Culleton R, Kaneko O: Erythrocyte binding ligands in malaria parasites: intracellular trafficking and parasite virulence. Acta Trop. 2010, 114: 131-137. 10.1016/j.actatropica.2009.10.025.CrossRefPubMed
52.
go back to reference Otsuki H, Kaneko O, Thongkukiatkul A, Tachibana M, Iriko H, Takeo S, Tsuboi T, Torii M: Single amino acid substitution in Plasmodium yoelii erythrocyte ligand determines its localization and controls parasite virulence. Proc Natl Acad Sci USA. 2009, 106: 7167-7172. 10.1073/pnas.0811313106.PubMedCentralCrossRefPubMed Otsuki H, Kaneko O, Thongkukiatkul A, Tachibana M, Iriko H, Takeo S, Tsuboi T, Torii M: Single amino acid substitution in Plasmodium yoelii erythrocyte ligand determines its localization and controls parasite virulence. Proc Natl Acad Sci USA. 2009, 106: 7167-7172. 10.1073/pnas.0811313106.PubMedCentralCrossRefPubMed
53.
go back to reference Yoeli M, Hargreaves B, Carter R, Walliker D: Sudden increase in virulence in a strain of Plasmodium berghei yoelii. Ann Trop Med Parasitol. 1975, 69: 173-178.PubMed Yoeli M, Hargreaves B, Carter R, Walliker D: Sudden increase in virulence in a strain of Plasmodium berghei yoelii. Ann Trop Med Parasitol. 1975, 69: 173-178.PubMed
Metadata
Title
Anti-malarial activity of geldanamycin derivatives in mice infected with Plasmodium yoelii
Authors
Rubul Mout
Zhi-Dong Xu
Angela K H Wolf
Vincent Jo Davisson
Gotam K Jarori
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2012
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-11-54

Other articles of this Issue 1/2012

Malaria Journal 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.